| 6521/13381 | US=9 / Urologia Keller ET, Hall CL. Pathophysiology of prostate cancer bone metastasis. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 245-54. ISBN 978-1-60327-831-7. FISIOPATOLOGIA DA PROSTATA; METASTASE OSSEA DO CANCER; CANCER DE PROSTATA; METASTASE OSSEA; RANKL; PROTEINA MORFOGENETICA OSSEA |
| 6522/13381 | US=9 / Urologia Sartor O, Venugopal DR. Radiopharmaceuticals. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 255-66. ISBN 978-1-60327-831-7. RADIOFARMACOS; SAMARIO-EDTMP; CLORETO DE ESTRONCIO; RADIO; FOSFORO; PALIACAO; CANCER DE PROSTATA; METASTASES OSSEAS; TERAPIA OSSO-ALVO |
| 6523/13381 | US=109 / Câncer Voss SD, Perez-Atayde A, Hoffer FA, Grier HE. Solid tumors in childhood. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 667-93. ISBN 978-0-323-05905-3. TUMORES SOLIDOS NA INFANCIA; RETINOBLASTOMA; TUMOR DE WILM'S; NEUROBLASTOMA; TUMORES HEPATICOS; RABDOMIOSARCOMA; TUMOR DE EWING; OSTEOSARCOMA |
| 6524/13381 | US=109 / Câncer Abramson JS, Scadden DT. AIDS-Associated malignancies. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 694-708. ISBN 978-0-323-05905-3. AIDS; SARCOMA DE KAPOSI; LINFOMA NAO HODGKIN; LINFOMA DE HODGKIN; LESOES EPITELIAIS ESCAMOSAS |
| 6525/13381 | US=109 / Câncer McCleary NJ, Skarin AT. Complications of cancer. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 709-20. ISBN 978-0-323-05905-3. CANCER. COMPLICACOES; NEUTROPENIA FEBRIL; HIPERCALCEMIA; HIPONATREMIA; SINDROME DE LISE TUMORAL; INSUFICIENCIA ADRENAL; ACIDOSE LACTICA; SINDROME DE HIPERVISCOSIDADE; LEUCOSTASE; HIPERCOAGULABILIDADE; ENDOCARDITE TROMBOTICA NAO-BACTERIANA; SINDROME ANTIFOSFOLIPIDE; SINDROME DE VEIA CAVA SUPERIOR; COMPRESSAO DA MEDULA ESPINHAL; METASTASES INTRACRANIANAS; CARCINOMATOSE LEPTOMENINGEA; SINDROME PARANEOPLASICA; DERRAMES MALIGNOS |
| 6526/13381 | US=109 / Câncer Eder JP, Skarin AT. Systemic and mucocutaneous reactions to chemotherapy. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 721-36. ISBN 978-0-323-05905-3. QUIMIOTERAPIA. REACOES; HIPERSENSIBILIDADE AGUDA; ALOPECIA; ESTOMATITE; MUCOSITE; DERMATITE; ERUPCOES CUTANEAS; HIPERPIGMENTACAO; ULCERACAO CUTANEA; ERITROMELALGIA; TOXICIDADE ORGANICA |
| 6527/13381 | US=9 / Urologia Saylor PJ, Smith MR. Bisphosnates for prevention and treatment of bone metastases. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 267-75. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; METASTASES OSSEAS; ODANACATIB; OSTEOCLASTOS; BISFOSFONATO; ESQUELETICOS RELACIONADOS COM EVENTOS; DENOSUMAB |
| 6528/13381 | US=9 / Urologia Nelson JB. Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 277-86. ISBN 978-1-60327-831-7. RECEPTORES DE ENDOTELINA; CASTRACAO CANCER DE PROSTATA. TERAPIAS; METASTASES OSSEAS; ENSAIOS CLINICOS; RECEPTORES DE ENDOTELINA; ENDOTELINA-1; CANCER DE PROSTATA |
| 6529/13381 | US=9 / Urologia Jensen AR, Szmulewitz RZ, Beer TM, Posadas EM. Calcitriol and vitamin D analogs. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 287-302. ISBN 978-1-60327-831-7. |
| 6530/13381 | US=9 / Urologia Madan RA, Gulley JL, Celestin J, Arlen PM, Schlom J. Cancer immunology, immunotherapeutics, and vaccine approaches. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 305-19. ISBN 978-1-60327-831-7. CANCER DE IMUNOLOGIA; IMUNOTERAPIA; VACINA DO CANCER; CANCER DE PROSTATA |
| 6531/13381 | US=9 / Urologia Higano CS. Sipuleucel-T: autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 321-27. ISBN 978-1-60327-831-7. SIPULEUCEL-T; IMUNOTERAPIA CELULAR AUTOLOGA; CANCER DE PROSTATA; METASTATICO RESISTENTE A CASTRACAO; HORMONIO REFRATARIO; PROVENCE; IMUNOTERAPIA CELULAR AUTOLOGA; RESISTENTE A CASTRACAO; APC8015 |
| 6532/13381 | US=9 / Urologia Patel LR, Simons JW. GM-CSF gene-transduced prostate cancer vaccines: GVAX. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 329-42. ISBN 978-1-60327-831-7. |
| 6533/13381 | US=9 / Urologia Harzstark AL, Fong L. CTLA-4 blockade for prostate cancer treatment. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 243-8. ISBN 978-1-60327-831-7. |
| 6534/13381 | US=9 / Urologia Parnes HL, House MG, Tanfrea JA. Prostate cancer chemoprevention strategies. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 351-62. ISBN 978-1-60327-831-7. QUIMIOPREVENCAO DO CANCER DE PROSTATA; QUIMIOPREVENCAO; DESENVOLVIMENTO DE AGENTES; DESFECHOS DO ESTUDO; COORTES; PCPT; REDUCE |
| 6535/13381 | US=9 / Urologia Chan JM, Richman EL. Diet and prostate cancer incidence, recurrence, and progression risk. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 363-73. ISBN 978-1-60327-831-7. |
| 6536/13381 | US=9 / Urologia Lucia MS, Lambert JR, Platz EA, Marzo AM. Inflammation as a target in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 375-86. ISBN 978-1-60327-831-7. INFLAMACAO; CANCER DE PROSTATA; CARCINOGENESE; QUIMIOPREVENCAO; QUIMIOTERAPIA; CITOCINAS; INFLAMACAO; ESTRESSE OXIDATIVO |
| 6537/13381 | US=9 / Urologia Alva AS, Bradley DA, Hussain M. Challenges for the development of new agents in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 389-97. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; NOVOS AGENTES DIRECIONADOS; DESAFIOS; DESENVOLVIMENTO DE MEDICAMENTOS |
| 6538/13381 | US=9 / Urologia Ning YM, Dagher RN, Pazdur R. FDA approval of prostate cancer treatments. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 399-405. ISBN 978-1-60327-831-7. FDA DOS TRATAMENTOS DO CANCER DE PROSTATA; APROVACAO DE MEDICAMENTOS; DESENVOLVIMENTO DE MEDICAMENTOS; ENDPOINTS; FDA; ANALISE POST-HOC; CANCER DE PROSTATA; ANALISE DE SUBGRUPO; PARAMETROS DE SUBSTITUICAO; SOBREVIVENCIA |
| 6539/13381 | US=9 / Urologia Gross M, Nepomuceno EM, Agus DB. Applications of proteomics in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 407-17. ISBN 978-1-60327-831-7. PROTEOMICA; CANCER DE PROSTATA; ESPECTROMETRIA DE MASSA; BIOMARCADOR; ANTIGENO PROSTATICO ESPECIFICO; IMUNO-HISTOQUIMICA |
| 6540/13381 | US=23-E / Câncer Alcázar JL. Distinguishing benign from malignant complex adnexal masses in ovarian cancer: two-dimensional power-doppler imaging. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: ovarian cancer, renal cancer, urogenitary cancer, urinary bladder cancer, cervical uterine cancer, skin cancer, leukemia, multiple myeloma and sarcoma. New York: Springer, 2010. p. 23-33. ISBN 978-90-481-2917-1. DISTINGUIR BENIGNAS DAS MALIGNAS; MASSAS ANEXIAIS EM CANCER DE OVARIO |